LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.27 -0.78

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.26

Максимум

1.32

Ключови измерители
By Trading Economics
Приходи	17M -26M
Служители	171
EBITDA	19M -23M

Препоръки
By TipRanks
Препоръки	Продай
12-месечна прогноза	+55.04% upside

Дивиденти
By Dow Jones
Следващи печалби	5.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-27M 76M
Предишно отваряне	2.05
Предишно затваряне	1.27

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.02.2026 г., 23:53 ч. UTC

Горещи акции

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27.02.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27.02.2026 г., 17:55 ч. UTC

Горещи акции

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27.02.2026 г., 23:46 ч. UTC

Придобивния, сливания и поглъщания

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27.02.2026 г., 23:33 ч. UTC

Придобивния, сливания и поглъщания

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

27.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

27.02.2026 г., 21:30 ч. UTC

Печалби

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27.02.2026 г., 21:30 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27.02.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27.02.2026 г., 21:17 ч. UTC

Печалби

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27.02.2026 г., 21:10 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27.02.2026 г., 21:09 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27.02.2026 г., 21:00 ч. UTC

Печалби

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27.02.2026 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27.02.2026 г., 20:24 ч. UTC

Пазарно говорене

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27.02.2026 г., 20:23 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27.02.2026 г., 20:12 ч. UTC

Пазарно говорене

Nike Seen With Further Challenges in China -- Market Talk

27.02.2026 г., 19:44 ч. UTC

Пазарно говорене

Gold Caps Historic Month -- Market Talk

27.02.2026 г., 19:39 ч. UTC

Печалби

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27.02.2026 г., 19:38 ч. UTC

Печалби

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27.02.2026 г., 18:53 ч. UTC

Придобивния, сливания и поглъщания

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27.02.2026 г., 18:45 ч. UTC

Печалби

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27.02.2026 г., 18:45 ч. UTC

Пазарно говорене

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

27.02.2026 г., 17:07 ч. UTC

Печалби

Pemex Cuts 4Q Loss As Operating Results Improve

27.02.2026 г., 17:00 ч. UTC

Пазарно говорене

Corn Rides Oil Momentum Higher -- Market Talk

27.02.2026 г., 16:31 ч. UTC

Пазарно говорене

Canadian Economy Shows Resilience -- Market Talk

27.02.2026 г., 16:17 ч. UTC

Пазарно говорене

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27.02.2026 г., 15:49 ч. UTC

Печалби

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

55.04% нагоре

12-месечна прогноза

Среден 2 USD 55.04%

Висок 2 USD

Нисък 2 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Продай

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.